During the past decade, BHI of Omsk region Clinical Oncology Dispensary conducted 115 clinical trials. In the 10-year time frame, 115 clinical trials started and 44 clinical trials were completed, i.e. on average, 38.3% percent of trials that started reached the finish line to date. In the past 5 years, 56 clinical trials started and 33 clinical trials were completed. i.e. 58.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "BHI of Omsk region Clinical Oncology Dispensary" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Pfizer" with 13 trials sponsored, "Janssen Research & Development, LLC" with 11 trials sponsored, "Merck Sharp & Dohme LLC" with 9 trials sponsored and "Bayer" with 9 trials sponsored. Other sponsors include 72 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "BHI of Omsk region Clinical Oncology Dispensary" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Bristol-Myers Squibb" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "BHI of Omsk region Clinical Oncology Dispensary" are "Prostatic Neoplasms" (6 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Crohn Disease" (4 trials), "Ulcerative Colitis" (4 trials) and "Colitis, Ulcerative" (3 trials). Many other conditions were trialed in "BHI of Omsk region Clinical Oncology Dispensary" in a lesser frequency.

Most popular intervention types in "BHI of Omsk region Clinical Oncology Dispensary" are "Drug" (121 trials), "Biological" (26 trials), "Other" (12 trials), "Procedure" (4 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Pembrolizumab" (12 trials), "Carboplatin" (10 trials), "Docetaxel" (10 trials) and "Paclitaxel" (9 trials). Other intervention names were less common.

The vast majority of trials in "BHI of Omsk region Clinical Oncology Dispensary" are 101 trials for "All" genders, 20 trials for "Male" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "BHI of Omsk region Clinical Oncology Dispensary". undefined are not yet recruiting, 29 are recruiting, 43 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 46 completed trials in BHI of Omsk region Clinical Oncology Dispensary, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in BHI of Omsk region Clinical Oncology Dispensary, 6 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 99 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".